Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Moderate to Severe Hidradenitis Suppurativa
NCT05620836Phase 3Completed
- Sponsor
- Incyte
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS) (3 arms), sponsored by Incyte. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 at 54 weeks. Started Feb 2023; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05620836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620836.